



RECENT DOWNGRADES - US

Here is a selected list of US stocks (mid cap and large cap) that after recording robust gains over the last 12 months have been recently downgraded to a (C) rating by Trendrating, pointing to an opportunity to take some profits.

Trendrating – delivering measurable alpha. Measurable. Actionable. Repeatable.

October 8, 2019

Trendrating

Trendrating is the leader in “**trend capture**” models, analytics and technology, serving 100+ institutions worldwide and premier partners including Euronext .

Trendrating provides an innovative , well proven set on analytics to assess and rate the quality of price trends. **The ability to capture trends , profiting from bull markets and avoiding bear phases is the key to superior performance on a consistent basis.** Trendrating makes possible to quickly analyze trends using a rating system where A and B identify bull trends and C and D point to bear trends. This rating approach captures in a systematic and unbiased way medium term price trends that can impact yearly portfolio returns. The rating of trends is additional market intelligence designed to enrich the investment decision process and maximize returns while improving risk control.

Trendrating offers a well validated rating methodology to measure trends (A, B, C, D) easy to integrate into most strategies and models.

A = strong bull trend

B = beginning of a bull trend

C = inception of a bear trend

D = strong bear trend







With Trendrating you can evaluate the direction and the quality of medium to long-term price trends for stocks, ETFs, indices, sectors and countries.

Trendrating is equally effective at identifying meaningful trends at the macro level, as well as screening from the bottom up to validate or generate new ideas.

Stocks List

Ticker	Name	Market cap	Price	Market	Sector	Rating	Rated on	Since rated	Last month
SAGE	Sage Therapeutics	7.27B	\$ 140.72	United States	Pharmaceuticals & Biotechnology	C	2019-09-24	-9.43%	-6.63%
TTD	The Trade Desk	7.58B	\$ 194.04	United States	Media	C	2019-09-09	-9.19%	-9.19%
OLED	Universal Display	7.77B	\$ 165.05	United States	Electronic & Electrical Equipment	C	2019-09-16	-7.25%	-21.76%
EXAS	Exact Sciences	12.00B	\$ 92.66	United States	Pharmaceuticals & Biotechnology	C	2019-09-25	-4.75%	-14.79%
RPD	Rapid7	2.37B	\$ 48.54	United States	Software & Computer Services	C	2019-09-10	-2.73%	-7.24%
FDS	Factset Research Systems	9.16B	\$ 239.44	United States	Media	C	2019-09-26	-2.55%	-10.92%
ENSG	Ensign	2.11B	\$ 39.43	United States	Health Care Equipment & Services	C	2019-09-09	-2.25%	-2.25%
NEO	Neogenomics	2.10B	\$ 20.24	United States	Health Care Equipment & Services	C	2019-09-24	-1.84%	-11.23%
VRSN	Verisign	21.71B	\$ 183.44	United States	Software & Computer Services	C	2019-09-24	-1.79%	-9.13%
AVLR	Avalara	5.33B	\$ 70.58	United States	Software & Computer Services	C	2019-09-10	-1.19%	-5.64%

Graphs



C Ensign (ENSG)

Rated on: 2019-09-09 | Since C: -2.25%

**C** Neogenomics (NEO)

Rated on: 2019-09-24 | Since C: -1.84%

**C** Verisign (VRSN)

Rated on: 2019-09-24 | Since C: -1.79%

**C** Avalara (AVLR)

Rated on: 2019-09-10 | Since C: -1.19%



The evaluations, rankings and information provided by Trendrating (the "Services") are provided solely for the use of finance professionals (the "Users") who have been issued a license to use the Services by Trendrating and who, by nature of their status as investment professions understand, or are expected to understand, the complexity of finance products, the functioning of the markets and the risks inherent in them. The Services are not offered for use by persons not employed or actively working as professionals in the finance and investment industry. The Services are to be used entirely at the risk of the Users. Included in the Services are forward-looking statements that are based on observations, assumptions and calculations that reflect Trendrating's expectations. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to materially differ from those expectations. The Services are not intended to constitute a recommendation of any specific security or financial product and are to be implemented solely in conjunction with or as part of a complete investment evaluation conducted by the Users. Under no circumstances shall Trendrating, its officers, directors, employees or agents be liable for any damages, lost profits or investment losses that result in any way from use of the Services or any interruptions, errors or delays in the Services.

www.trendrating.com